Search results
Results from the WOW.Com Content Network
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. [5] It is delivered subcutaneously either by injection or from an insulin pump. [5] [6] Onset of effects typically occurs within 30 minutes and lasts about 5 hours. [5]
NPH insulin is cloudy and has an onset of 1–3 hours. Its peak is 6–8 hours and its duration is up to 24 hours. [9]It has an intermediate duration of action, meaning longer than that of regular and rapid-acting insulin, and shorter than long acting insulins (ultralente, glargine or detemir).
Faster-acting insulins peak quickly and are subsequently metabolized, while longer-acting insulins tend to have extended peak times and remain active in the body for more significant periods. [5] Examples of rapid-acting insulins (peak at ~1 hour) are: [citation needed] Insulin lispro (Humalog) Insulin aspart (Novolog) Insulin glulisine (Apidra)
People with insulin-dependent diabetes typically require some base level of insulin (basal insulin), as well as short-acting insulin to cover meals (bolus also known as mealtime or prandial insulin). Maintaining the basal rate and the bolus rate is a continuous balancing act that people with insulin-dependent diabetes must manage each day.
There are several types of insulin that are commonly used in medical practice, with varying times of onset and duration of action. [32] - Rapid acting (i.e. insulin lispro) with onset in 15 minutes and duration of about 4 hrs. - Short acting (i.e. regular insulin) with onset in 30 minutes and duration of about 6 hrs.
The market size for fast-acting insulin is well worth a second chance. Eli Lilly 's ( NYS: LLY ) Humalog insulin sales, for instance, reached almost $2.4 billion in fiscal 2011. 2.
New York Magazine cited witnesses in an August article who said the brothers often spoke of "running a train," slang for the act of gang rape, when they were in school.
This is because many of the principles of insulin dosage adjustment are remarkably similar in both type 1 and type 2 diabetes mellitus, and even without an endogenous insulin secretion model function, AIDA still can offer realistic simulations (from an educational perspective) for people with non-insulin dependent (type 2) diabetes mellitus ...